NervGen Pharma - CEO Paul Brennan
CEO Paul Brennan
Source: Longevity Technology
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NervGen Pharma (NGEN) is partnering with Imeka Solutions to advance its NVG-291 compound
  • The company intends to utilize Imeka’s imaging technology as a sensitive pharmacodynamic biomarker for NVG-291
  • NervGen is currently working on a Phase 1 trial of the treatment in healthy subjects and is planning a Phase 1b/2 trial in Alzheimer’s disease patients
  • NervGen Pharma is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases
  • NervGen Pharma Corp. (NGEN) is up 4.72 per cent, trading at $2.22 per share

NervGen Pharma (NGEN) is partnering with Imeka Solutions to advance its NVG-291 compound.

Imeka is currently the only neuroimaging company that combines artificial intelligence and diffusion imaging to obtain high-resolution images of white matter in the brain.

NervGen intends to utilize Imeka’s imaging technology as a sensitive pharmacodynamic biomarker for NVG-291 in its clinical trials.

NVG-291 modulates protein tyrosine phosphatase (PTPσ), the key receptor for chondroitin sulfate proteoglycans (CSPGs).

PTPσ and CSPGs have been shown to impede repair following injury to the nervous system, whether a result of trauma, such as in the case of spinal cord injury or traumatic brain injury or disease-specific mechanisms, such as Alzheimer’s disease or multiple sclerosis.

NervGen is currently working on a Phase 1 trial of the treatment in healthy subjects and is planning a Phase 1b/2 trial in Alzheimer’s disease patients once Phase 1 is complete. A concurrent trial will test NVG-291 in spinal cord injury and multiple sclerosis patients.

“We are very excited to apply Imeka’s advanced imaging technology to assess the biological activity of NVG-291 in clinical trials,” said Dr. Daniel Mikol, NervGen’s Chief Medical Officer.

“Incorporating Imeka’s imaging technology in our clinical trials will nicely complement other outcome measures,” he added, “to strengthen the evidence supporting that NVG-291 can also repair nervous system damage in humans.”

Imeka works in collaboration with pharmaceutical and biotechnology companies in the development of treatments for neurodegenerative diseases, such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.

NervGen Pharma is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases.

NervGen Pharma Corp. (NGEN) is up 4.72 per cent, trading at $2.22 per share as of 2:56 pm ET.

More From The Market Herald

" BlackBerry (TSX:BB) launches Google Chrome Enterprise Management

BlackBerry (BB) has launched Chrome Enterprise Management under its UEM service.
Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.

" Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
FansUnite - CEO, Scott Burton.

" FansUnite (CSE:FANS) reports Q1 2022 financial results

FansUnite (FANS) has filed its interim financial statements for the three months ended March 31, 2022.